And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Psoriasis

News | October 18, 2019

UCB Presents New Data for Cimzia, Investigational Bimekizumab

Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of...

Read More

News | October 18, 2019

Data Show Long-term Benefit for Sun Pharma's Ilumya

Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people...

Read More

News | October 18, 2019

Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PA

New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV)...

Read More

New Evidence for Psoriasis Seasonality

There may indeed be a seasonality to psoriasis—if trends in online searches about the disease are an indication. Researchers analyzed relative search volume for psoriasis and related terms in Google Trends from January 2004 to...

Read Article

Assessing Comorbidities in Psoriasis Patients: Key to Comprehensive Care

The dermatology community has over the past several years gained important insights into the comorbidities that may exist alongside psoriasis. Dermatology clinicians who focus on issues like metabolic syndrome are, “realizing that a...

Read Article

Advertisement

The Latest in Psoriasis

Advertisement

VIDEO | July 29, 2019

Nanotechnology Advances

Meeting Coverage | 2019 AAD Summer Meeting

New York, NY: July 25 - 28, 2019

Adam Friedman, MD, FAAD

View more